Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy

Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy

Albumin conjugates can enhance drug delivery. Here, the authors repurpose albumin-binding Evans blue to develop nanovaccines that co-deliver adjuvants and tumor neoantigens to antigen-presenting cells in lymph nodes, resulting in potent and durable antitumour immunity in combination immunotherapy.

Guardado en:
Detalles Bibliográficos
Autores principales: Guizhi Zhu, Geoffrey M. Lynn, Orit Jacobson, Kai Chen, Yi Liu, Huimin Zhang, Ying Ma, Fuwu Zhang, Rui Tian, Qianqian Ni, Siyuan Cheng, Zhantong Wang, Nan Lu, Bryant C. Yung, Zhe Wang, Lixin Lang, Xiao Fu, Albert Jin, Ido D. Weiss, Harshad Vishwasrao, Gang Niu, Hari Shroff, Dennis M. Klinman, Robert A. Seder, Xiaoyuan Chen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/6c1cbd8acb2f42149db4a8201852deb6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Albumin conjugates can enhance drug delivery. Here, the authors repurpose albumin-binding Evans blue to develop nanovaccines that co-deliver adjuvants and tumor neoantigens to antigen-presenting cells in lymph nodes, resulting in potent and durable antitumour immunity in combination immunotherapy.

Ejemplares similares